Progress Against Lung Cancer. 1970–1979 Progress Against Lung Cancer 1970–1979 Mid-1970s: Chemotherapy combinations prove effective in small cell lung.

Slides:

Advertisements

Similar presentations

The BIG Kahuna among Tumors

Advertisements

Major Cancer Milestones

Progress Against Breast Cancer

Progress Against Prostate Cancer. 1970–1979 Progress Against Prostate Cancer 1970–1979 Early 1970s: Radioactive ''seeds'' proven effective for prostate.

Progress Against Stomach Cancer. 1980–1989 Progress Against Stomach Cancer 1980– : Combination chemotherapy improves outcomes for advanced stomach.

Progress Against Lymphoma. 1970–1979 Progress Against Lymphoma 1970– : FDA approves doxorubicin, a vital part of combination chemotherapy.

Progress Against Bladder Cancer. Pre-1970 Progress Against Bladder Cancer Pre : Tool offers view inside bladder for first time.

Progress Against Ovarian Cancer. 1970–1979 Progress Against Ovarian Cancer 1970– : First effective combination chemotherapy regimen for ovarian.

Progress Against Testicular Cancer. 1970–1979 Progress Against Testicular Cancer 1970– : Two new drugs produce first complete remissions in advanced.

Progress Against Cervical Cancer. 1980–1989 Progress Against Cervical Cancer 1980– –1984: HPV virus is discovered to cause cervical cancer.

Progress Against Head and Neck Cancer. 1970–1979.

Progress Against Melanoma. 1970–1979 Progress Against Melanoma 1970– : Hereditary syndrome linked to increased melanoma risk.

Progress Against Leukemia. 1970–1979 Progress Against Leukemia 1970– : FDA approves doxorubicin.

Progress Against Kidney Cancer. 1970–1979 Progress Against Kidney Cancer 1970– : Removing just part of the cancerous kidney is proven safe and.

Progress Against Pancreatic Cancer. 1970–1979 Progress Against Pancreatic Cancer 1970– s: Tobacco use found to cause pancreatic cancer.

Progress Against Liver Cancer. 1970–1979 Progress Against Liver Cancer 1970– : First study finds chemotherapy effective for liver cancer.

Presenter Name(s) Issue date National Student.

First cases of AIDS identified.

CTOS Herman Suit CTOS Special Award Lecture November 2005 Professor Herman D Suit Massachusetts General Hospital Dept. of Radiation Oncology Boston.

Trends in incidence and mortality, England 1989 to 2010.

Zeroing in on Non-Small Cell Lung Cancer: Integrating Targeted Therapies into Practice.

Shyamala Maherswaran, Ph.D. et al. Sarah Gomez and Rachael Holmes Detection of Mutations in EGFR in Circulating Lung-Cancer Cells.

Treatment in Advanced Non-Small Cell Lung Cancer.

Oncology and Palliative Care: Promoting the Comfort and Cure Model Parag Bharadwaj, MD FAAHPM.

Vinni Swad Zander Thompson

Matthew Kilmurry, M.D. St. Mary’s General Hospital Grand River Hospital.

Screening for Lung Cancer Jess Dalehite, M.D. Southwest Medical Imaging Midland Memorial Hospital.

Detection of Mutations in EGFR in Circulating Lung-Cancer Cells Colin Reisterer and Nick Swenson S. Maheswaran et al. The New England Journal of Medicine.

Childhood Cancer Gabby Kulikowski & Kellie Campbell.

Lung Cancer Lung cancer is a disease in which body cells grow uncontrollably starting in the lungs.

Basics of Pediatric Oncology Margret E. Merino, MD Pediatric Hematology/Oncology WRAMC.

Cancer is a disease marked by the uncontrolled growth of abnormal cells. The abnormal cells no longer do the work that the normal cells did, and they.

By: Sydney Trecarichi, Hayley Cash and Jordan Wittig Esophageal Cancer.

Types of Cancer. What is Cancer? Cancer is an uncontrolled growth of cells in the body. Cancer happens when cells divides too quickly and when cell "forgets"

Lung cancer, like all cancers, happens with abnormal cell function. Lung cancer is a very life threatening cancer, as it tends to spread early and is.

New Developments in Cancer Treatment Dulcinea Quintana, MD.

Treatment options depend on the following: – The stage of the cancer – Whether the cancer has recurred – The patient’s general health.

Lung Cancer Emily Cauchon Katie Reeves Emily Cauchon Katie Reeves.

WHAT ARE THE RISK FACTORS FOR LUNG CANCER? SMOKING.

 Small cell lung cancer is named based on the size of the cells that cause the cancer. It accounts for about 20% of lung cancer cases.  It also referred.

Treatment Regimens of HER2+ Adjuvant Patients (Actuals) Source: Genentech ASCO 2005 (data release) Nov 2006 (Approval)

Most common cancers among MEN 1.Prostate (128.3) (15.6% death rate) 2.Lung (73) (79.3% death rate) 3.Colorectal (46.1) (39.3% death rate) Most Common Cancers.

Lung Cancer By: Mitch Harbaugh, Michelle Roa, Huba Nasir, Alexandra Ali, Becca Cohen.

Personalized medicine in lung cancer R4 김승민. Personalized Medicine in Lung Cancer patients with specific types and stages of cancer should be treated.

By: Thien Bui and Reshma Neupane 1. Lung Cancer Lung Cancer is an uncontrolled growth of abnormal cells in one or more lungs 2 Common Types of Lung Cancer:

Lung Cancer WHAT IT IS & WHAT YOU NEED TO KNOW. What is lung cancer? 2 types: 1. Non-small cell lung cancer (NSCLC). 85% of cases 2. Small cell lung cancer.

 Lung Cancer Sydney Freedman and Rachel Rea. Causes  No exact cause  Smokers and non-smokers can get lung cancer  Smoke causes cancer by damaging.

Clinical Cancer Advances 2010 ASCO’s Annual Report on Progress Against Cancer.

Clinical Cancer Advances 2011 ASCO’s seventh annual Clinical Cancer Advances report identifies this year’s most significant clinical.

Cancer Types Jeopardy.

Clinical and Research Updates in Gynecologic Oncology

Lung Cancer Angel.

Instructor Kathleen Gamblin, RN, BSN, OCN Oncology Nurse Navigator

The Uganda Cancer Institute Experience Walusansa Victoria.

Bronchial Carcinoma Part 2

PHEN Clinical Trials Rally

Progressive brain metastases in an EGFR mutated adenocarcinoma of the lung: Response to gefitinib after progression on erlotinib C. Leitner, R. von Moos,

Christopher S. Lathan, M. D. , M. S. , M. P. H

The Nurse View: Best Practices in Advanced Non-Small Cell Lung Cancer

Meta-analysis of randomised phase III clinical trials comparing EGFR tyrosine kinase inhibitor (TKI) shows that male patients with non-small cell lung.

Clinical marker confirmation using centrally assessed progression-free survival data in patients with advanced non-small cell lung cancer with non-squamous.

Defining Patient-Centered Care: Spotlight on Advanced Non-Small Cell Lung Cancer.

Meta-Analysis of First-Line Therapies in Advanced Non–Small-Cell Lung Cancer Harboring EGFR-Activating Mutations Benjamin Haaland, PhD, Pui San Tan,

Quality Improvement and Molecular Profiling in Advanced Non-Small Cell Lung Cancer.

General strategies of Cancer Treatment and evaluation of Response

Updates in Best Practices in Non-Small Cell Lung Cancer

Presentation transcript:

Progress Against Lung Cancer

1970–1979

Progress Against Lung Cancer 1970–1979 Mid-1970s: Chemotherapy combinations prove effective in small cell lung cancer

Progress Against Lung Cancer 1980–1989

Progress Against Lung Cancer 1980– : Second-hand smoke formally declared a carcinogen

Progress Against Lung Cancer 1980– : Scientists discover key genetic vulnerability in tumor cells – EGFR

Progress Against Lung Cancer 1990–1999

Progress Against Lung Cancer 1990– –1992: Combining chemotherapy and radiation prolongs survival for non-small cell lung cancer

Progress Against Lung Cancer 1990– : Simultaneous radiation and chemotherapy boosts survival for small cell lung cancer

Progress Against Lung Cancer 1990–1999 Mid-1990s: New generation of chemotherapy drugs for non-small cell lung cancer

Progress Against Lung Cancer 1990– : Analysis affirms benefits of chemotherapy for advanced non-small cell lung cancer

Progress Against Lung Cancer 1990– : Topotecan approved as second round of treatment for small cell lung cancer

Progress Against Lung Cancer 1990– : Cranial radiation reduces risk of small cell lung cancer spreading to the brain 1999: Simultaneous chemotherapy and radiation proven most effective for stage III non-small cell lung cancer 1999: Giving radiation to the chest twice-daily increases survival for small cell lung cancer

Progress Against Lung Cancer 2000–Present

Progress Against Lung Cancer 2000–Present 2000: Study links household radon exposure to lung cancer 2000: Second round of chemotherapy boosts survival in advanced non-small cell lung cancer

Progress Against Lung Cancer 2000–Present 2003: First targeted drug approved for non-small cell lung cancer

Progress Against Lung Cancer 2000–Present 2004: Studies show that specific EGFR mutations are associated with response to gefitinib 2004: FDA approves second targeted drug, erlotinib, for non-small cell lung cancer 2004–2005: Adjuvant therapy proven effective in lung cancer

Progress Against Lung Cancer 2000–Present 2005: Anti-angiogenic drug bevacizumab extends survival for advanced lung cancer 2005: New project to map lung cancer genome

Progress Against Lung Cancer 2000–Present 2008: Circulating tumor cells in the blood can help track treatment response in select patients

Progress Against Lung Cancer 2000–Present 2009: Maintenance therapy improves survival for advanced non-small cell lung cancer

Progress Against Lung Cancer 2000–Present 2010: Older patients should be considered for the same aggressive chemotherapy as younger patients 2010: Adding palliative care to standard chemotherapy improves survival for advanced lung cancer patients 2010: New lung cancer staging system is adopted 2010: Drug aimed at a newly identified target causes dramatic tumor shrinkages 2010: CT scanning reduces lung cancer deaths among heavy smokers

Progress Against Lung Cancer Five-Year Survival Source: National Cancer Institute

Progress Against Lung Cancer Mortality Source: National Cancer Institute

Progress Against Lung Cancer New Cases Source: National Cancer Institute

Visit CancerProgress.Net for an interactive timeline of progress against a range of common cancers CancerProgress.Net is a project of the American Society of Clinical Oncology, which represents nearly 30,000 physicians who treat people with cancer and research new cures